Search results :

Pioglitazone

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: A10BG03

Side effects

Options: Show MedDRA Preferred Terms,   display all 30 labels

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Hypoglycaemia 0% - 30.6% 7.1% - 18.8% x x x x x x x x x x x x x x x x x x x x
Upper respiratory tract infection common, 7.5% - 13.2% 6.2% - 8.5% x x x x x x x x x x x x x x x x x x x x
Headache 2.8% - 9.1% 2% - 6.9% x x x x x x x x x x x x x x x x x x x x
Respiratory tract infection 7.5% - 8.9% 6.2%
Cardiac failure 8.1% 6.1% x x x x x
Weight increased common, 5.5% - 26.2% 0.9% - 1.3% x x x x x x x x x x x x x x
Pain in extremity 6.4% 5.7% x x x x x x
Sinusitis uncommon, 3.6% - 6.3% 2.9% - 4.6% x x x x x x x x x x x x x x x x x x x x
Back pain 3.1% - 5.9% 2% - 5.1% x x x x x x x x x
Myalgia 2.8% - 5.4% 1.3% - 2.7% x x x x x x x x x x x x x x x x x x
Tooth disorder 2.6% - 5.3% 1.5% - 2.3% x x x x x x x x x x x x
Chest pain 5.1% 5% x x x x x x x x x x x
Pharyngitis 2.7% - 5.1% 0.3% - 0.8% x x x x x x x x x x x x x x x x x x
Diabetes mellitus exacerbated 5.1% 8.1% x x x x x x x x x x x
Hypoaesthesia common x x x x x x x
Visual disturbance common x x x x x x x
Arthralgia 3.1% - 5.4% 2% - 3.1% x x x
Asthenia 4.1% 2% x
Oedema postmarketing, 0% - 26.7% 0.6% - 15.3% x x x x x x x x x x x x x x x x x x x x
Bronchitis 2.8% 2% x x x
Malaise 2.8% 1.3% x
Urinary tract infection 2.7% 1.6% x x x x x x x
Diarrhoea 2.1% - 4.6% 2% - 6.5% x x x x x x x x x x
Fatigue 2.5% 2.4% x x x
Accidental injury 2.2% 1.5% x x x x
Gastroenteritis 2.1% 1.3% x
Influenza 2.1% 0.7% x
Cramps of lower extremities 2.1% 1.1% x
Abdominal pain upper 2.1% 0.7% x
Tooth abscess 2.1% 0% x
Abnormal vision 2.1% 1.4% x
Bladder cancer uncommon x x x x x x x x x
Insomnia uncommon x x
Fracture postmarketing, common x x x x x x x x x x x x x x
Cardiac disorder postmarketing, 0% x x x x x x x x
Cardiac failure congestive postmarketing, 5.72% 4.1% x x x x x x x
Hepatitis postmarketing x x x x x x
Hepatic failure postmarketing x x x x x x x x x x x x x x x x x x
Oedema peripheral postmarketing, 3.5% 3.3% x x x x x x x x x
Fatal outcomes postmarketing x x x x x x x x
Visual acuity reduced postmarketing x x x x x x x x x x x x x x x
Diabetic postmarketing x x x x x x x x x
Macular oedema postmarketing x x x x x x x x x x x x x x x x x
Worsening of diabetes postmarketing x x x x x x x x x
Congenital anomaly x
Anaphylactic shock x
Anaemia x x x x x x x x
Angina pectoris x x x
Angioedema x
Bladder neoplasm x x x x x x
Breast disorder x x
Breast feeding x
Transient ischaemic attack x x x
Infection x x
Connective tissue disorder x x
Cyst x x
Dizziness x x x x x x x x
Dyspnoea x x x x x x x
Eye disorder x x x
Flatulence x x x x x x x x
Gastrointestinal disorder x x
Glycosuria x x
Haematuria x x
Hyperglycaemia x x x x x x x x x x x
Hypersensitivity x
Hypertension 0% x x x x x x x x x
Immune system disorder x
Ischaemia 0% x x x
Mediastinal disorder x x
Myocardial infarction x x x x x x x x x
Neoplasm x x x x x x x x
Nervous system disorder x x
Polyp x x
Pregnancy x
Proteinuria x x
Pulmonary oedema
Cerebrovascular accident x x x x x x x x
Sweating x x
Urinary tract disorder x x
Urticaria x
Vertigo x x
Weight decreased x x
Generalised oedema x x x
Myocardial ischaemia x x x
Liver function test abnormal x x x x x x x x x x x x
Alanine aminotransferase increased x
Malnutrition x x
Unspecified disorder of skin and subcutaneous tissue x x
Volume plasma increased x x x x x x x x x x x
Increased appetite x x
Hepatic enzyme increased x x
Erectile dysfunction x x
Fluid retention x x x x x x
Pitting edema x x x
Developmental delay x
Electrocardiogram abnormal x x x
Infestation NOS x x
Blood and lymphatic system disorders x x
Ear and labyrinth disorders x x
Blood creatine phosphokinase increased x x x x x x x
Glycosylated haemoglobin decreased x x x x x
Drug-induced liver injury x x x x x x
Acute coronary syndrome x x x x x x
Hepatic impairment x
Hepatic enzyme decreased x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

PIOGLITAZONE HYDROCHLORIDE / ACTOS

Side effects:13
Source:FDA

pioglitazone HCl / Actos

Side effects:14
Source:FDA

PIOGLITAZONE HYDROCHLORIDE / ACTOS

Side effects:15
Source:FDA

PIOGLITAZONE HYDROCHLORIDE / ACTOS

Side effects:18
Source:FDA

pioglitazone

Side effects:19
Source:FDA Structured Product Label

PIOGLITAZONE HYDROCHLORIDE / ACTOS

Side effects:19
Source:FDA

PIOGLITAZONE

Side effects:34
Source:FDA Structured Product Label

pioglitazone

Side effects:34
Source:FDA Structured Product Label

PIOGLITAZONE

Side effects:34
Source:FDA Structured Product Label

PIOGLITAZONE

Side effects:35
Source:FDA Structured Product Label

pioglitazone

Side effects:37
Source:FDA Structured Product Label

pioglitazone hydrochloride / Vexazone

Side effects:37
Source:medicines.org.au

PIOGLITAZONE

Side effects:38
Source:FDA Structured Product Label

pioglitazone / pioglitazone

Side effects:54
Source:EMA

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label